Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,027 public trials 2,025 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

NCT05263583

Conditions
Burkitt Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, +24 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Sun Yat-sen University Cancer Center Guangzhou, China
  • Henan Cancer Hospital Henan, China
  • Shanghai East Hospital Pudong, China
View Trial Details
Active, Not Recruiting

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

NCT05885464

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Stanford University School of Medicine Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Chicago Chicago, Illinois, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
View Trial Details
Active, Not Recruiting

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

NCT04786028

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Nova Scotia Health - QEII Health Sciences Centre Halifax, Nova Scotia, Canada
  • Hamilton Health Sciences Centre Hamilton, Ontario, Canada
  • The Ottawa Hospital General Campus Ottawa, Ontario, Canada
View Trial Details
Active, Not Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

NCT05201248

Conditions
B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • The Fifth Medical Center of PLA General Hospital /ID# 230520 Beijing, Beijing Municipality, China
  • Peking University Third Hospital /ID# 228138 Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital /ID# 231890 Fuzhou, Fujian, China
  • Sun Yat-Sen University Cancer Center /ID# 228033 Guangzhou, Guangdong, China
View all 18 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Redondo Beach, California, United States
  • Research Site Fort Wayne, Indiana, United States
  • Research Site Wichita, Kansas, United States
View all 170 locations
View Trial Details
Active, Not Recruiting

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

NCT03150914

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Stanford University Palo Alto, California, United States
  • National Jewish Hospital Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
  • Loyola University Chicago, Illinois, United States
View Trial Details

Related conditions